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Questions under study: The diagnostic signifi-
cance of clinical symptoms/signs of influenza has
mainly been assessed in the context of controlled
studies with stringent inclusion criteria. There was
a need to extend the evaluation of these predictors
not only in the context of general practice but also
according to the duration of symptoms and to the
dynamics of the epidemic.
Principles: A prospective study conducted in
the Medical Outpatient Clinic in the winter sea-
son 1999–2000. Patients with influenza-like syn-
drome were included, as long as the primary care
physician envisaged the diagnosis of influenza.
The physician administered a questionnaire, a
throat swab was performed and a culture acquired
to document the diagnosis of influenza.
Results: 201 patients were included in the study.
52% were culture positive for influenza. By uni-
variate analysis, temperature >37.8 °C (OR 4.2;
95% CI 2.3–7.7), duration of symptoms <48 hours
(OR 3.2; 1.8–5.7), cough (OR 3.2; 1–10.4) and
myalgia (OR 2.8; 1.0–7.5) were associated with a
diagnosis of influenza. In a multivariable logistic
analysis, the best model predicting influenza was
the association of a duration of symptom <48 hours,
medical attendance at the beginning of the epi-
demic (weeks 49–50), fever >37.8 and cough, with
a sensitivity of 79%, specificity of 69%, positive
predictive value of 67%, negative predictive value
of 73% and an area under the ROC curve of 0.74.  
Conclusions: Besides relevant symptoms and
signs, the physician should also consider the dura-
tion of symptoms and the epidemiological context
(start, peak or end of the epidemic) in his appraisal,
since both parameters considerably modify the
value of the clinical predictors when assessing the
probability of a patient having influenza. 
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The recent marketing of antiviral drugs
against influenza has changed the diagnostic 
approach to this disease. Indeed, there is a need to
make the diagnosis as quickly as possible so that
the new drugs can be used appropriately [1–3]. The
general practitioner needs epidemiological, clini-
cal and/or laboratory tools to improve the reliabil-
ity of the diagnosis of influenza at first attendance. 
The diagnostic performance of clinical symp-
toms/signs of influenza has mainly been assessed
in the context of controlled studies (clinical trials
of new antiviral drugs) often using stringent inclu-
sion criteria. A temperature >37.8 °C, cough and
sudden onset of symptoms have been identified 
as indicators of influenza [4–11]. In the present
study, we wanted to assess these predictors in the
context of general practice and  more importantly,
the magnitude of their variation according to the 
duration of symptoms and the dynamic of the epi-
demic (start, peak and end). 
Design
Prospective study conducted during the winter sea-
son 1999–2000 at the Medical Outpatient Clinic, Univer-
sity Hospital of Lausanne, Switzerland, a primary care
centre that serves an urban population of approximately
150,000 inhabitants. The study was conducted within a
national surveillance programme of influenza epidemics
in Switzerland called Sentinella [12]. Throughout the
year, naso-pharyngal swabs are collected and tested for in-
fluenza and other infectious diseases from several institu-
tions (outpatient clinics) and private practices in Switzer-
land, in order to detect and monitor epidemic outbreaks.
The proportion of medical consultations for influenza-
like illness (% MC-ILI) is also reported, and is used to de-
scribe the dynamics of the influenza epidemic (by defini-
tion the threshold for an epidemic is 1.5%).
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Patients and procedure
Patients were recruited into the study by the physi-
cian on duty, if he/she felt that the symptoms or signs were
compatible with a diagnosis of influenza.1 There were no
specific criteria for inclusion or exclusion (such as those of
Sentinella surveillance in Switzerland, for example) in
order to avoid selection bias (patient with a high pre-test
probability) and to reflect the real practice. Following oral
consent, the physician administered a questionnaire to the
patient to collect demographic (i.e. age, sex) and clinical
data (i.e. symptoms of cough, sore throat, rhinitis, myal-
gia, headache, fatigue, chills/sweating, as well as the dura-
tion of symptoms from onset to medical attendance and
signs, mainly axillary temperature). A threshold value of
37.8° was used to define fever as in most comparable stud-
ies [3]. A throat-swab was performed and sent in medium
(Leibowitz, BSA, bicarbonate, hybrimax and gentamycin)
to the reference laboratory for the Sentinella Surveillance
Program (IKMI, St-Gallen, Switzerland) for  a MDCK
culture in order to identify influenza A and B viruses.
Data analysis
To measure the association between the explanatory
variables (duration of the symptoms, the period of the con-
sultation, axillary temperature of >37.8 °C, cough, sore
throat, rhinitis, myalgia, headache, fatigue, chills/sweat-
ing), and the outcome variable (presence of influenza A or
B in throat swab culture), we estimated the odds ratio with
the program CIA SOFTWARE version 2.0.0 from BMJ
using univariate analysis. For each of these variables, we
estimated the sensitivity (Se), specificity (Sp), positive and
negative predictive values (PPV/NPV). 
We then built a multivariable logistic model using
STATA 8.2 software, starting with a simple model includ-
ing only duration of symptoms and period of consultation.
The categories for the duration of symptoms were <24 h,
24–48 h and >48 h. The categories for the time-period of
consultation were: week 49–51 (pre-epidemic), 52–1 (peak
of the epidemic) and >1 (post-epidemic) [based on the pro-
portion of medical consultations due to flu-like syndromes
estimated by the Swiss infectious disease surveillance sys-
tem (Sentinella)]. We added step by step those clinical
variables with odds ratio higher than one. We retained in
the model variables for which the estimated odds ratio was
>1 (p-value <0.05). Working backwards, we proceeded to
a simplification in the definition of the categorical vari-
ables, using the deviance statistic to judge the loss of diag-
nostic power. The ROC curves of both the initial and the
final models were computed, as well as the sensitivity,
specificity, PPV and NPV. 
This study was conducted from December
1999 to February 2000. 222 patients were included
in the study and 21 patients with incomplete data
or where no throat-swab had been done were ex-
cluded from the analysis, 201 patients remained.
104 of 201 (52%) had a positive throat-swab for in-
fluenza, of which 103 were positive for influenza A
and one for influenza B. The mean age was simi-
lar in the group with positive culture (mean = 34.3
years, SD = 13) and with negative culture (mean =
34.3, SD = 12). Patients at the height of the epi-
demic were older than 60 years and half of them
tested positive for influenza. The demographical
characteristics as well as the prevalence of symp-
toms and signs among cases of influenza vs con-
trols are summarised in table 1. 
By univariate analysis, temperature >37.8 °C,
cough, duration of symptoms <48 hours before
consultation and myalgia were associated with a di-
agnosis of influenza.
Table 2 shows the diagnostic performance
(PPV, NPV, sensitivity and specificity) of clinical
variables for the diagnosis of influenza. 
We started to construct the multivariable lo-
gistic model with the two variables: time-period 
of consultation and duration of symptoms before
Results
Characteristics % (number) of  patients % (number) patients Odds CI 95%
with positive culture with negative culture Ratio*
(n = 104) (n = 97)
Female sex 53 (55) 46 (44) 1.3 0,8–2.3
Duration of symptoms before medical 66 (69) 38 (37) 3.2 1.8–5.7
attendance <48 h
Time-period of consultation
weeks 49–50 (pre-epidemic) 26 (27) 28 (27) 2.3 1.2–4.5
weeks 51–5 (epidemic and post-epidemic) 74 (77) 72 (70) ref
Temperature >37.8 °C 74 (77) 40 (39) 4.2 2.3–7.7
Cough 96 (100) 89 (86) 3.2 1.0–10.4
Temperature >37,8 °C and cough 72 (75) 37 (36) 4.4 2.4–7.9
Sore throat 75 (78) 75 (73) 1 0.5–1.9
Myalgia 94 (98) 86 (83) 2.8 1.0–7.5
Rhinitis 81 (84) 81 (79) 1 0.5–1.9
Headache 85 (88) 84 (81) 1.1 0.5–2.3
Fatigue 91 (95) 92 (89) 1 0.4–2.6
Chills/sweating 88 (91) 77 (75) 2.1 1.0–4.4
* by univariate analysis
Table 1
Demographical 
characteristics and
prevalence of 
symptoms and signs
among cases of in-
fluenza (culture +) 
vs controls (culture –).
1 This study was con-
ducted within the
Swiss national sur-
veillance program
of infectious dis-
eases “Sentinella”
and therefore no
ethical approval
was required. The
patients agreed 
to have a throat
swab taken and
that the results be
reported to the
medical and scien-
tific community.
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first medical attendance, each divided into three
categories as described in the data analysis section.
In this situation the area under the ROC curve was
0.69 with a prediction rule of 0.5, Se was 64% (IC
95% 54–74), Sp 64% (54–73), PPV 66% (56–75)
and NPV 63% (52–72) (see figure 1). We then
added step by step the variables with an estimated
OR >1, temperature >37.8, cough, and myalgia.
The latter symptom added nothing to the power of
the model and was thus withdrawn. Following this,
we replaced temperature >37.8° by continuous
temperature measurement. We then simplified the
three time-period categories into two (week 49–50
and week 51–5) and also the three categories of
duration of symptoms into two (<48 h and >48 h)
without changing the power of our model. Finally,
the model with two categories for time-period of
consultation and duration of symptoms, continu-
ous temperature and cough had an area under 
the ROC curve of 0.76 with a Se of 74% (65–82),
Sp of 69% (59–78), PPV of 72% (62–80) and NPV
of 71% (61–80) (see figure 2). When we replaced
continuous temperature by categorical tempera-
ture >37.8, the area under the ROC curve was 0.74
with a Se of 80% (70–87), Sp of 59% (48–
69), PPV of 67% (58–76) and NPV of 73% (62–82)
(see figure 3).
Symptoms and signs PPV NPV Se Sp
Cough 54 73 96 11
Sore throat 52 48 75 25
Rhinitis 52 47 81 19
Myalgia 54 70 94 14
Headache 52 50 85 17
Fatigue 52 47 91 8
Duration of symptoms <48 h 65 63 66 62
Chills/sweating 55 63 88 23
Temperature >37,8 °C 66 68 74 60
Cough + Temp. >37,8 °C 68 68 72 63
Table 2
Diagnostic perform-
ance: Positive Predic-
tive Value (PPV), 
sensitivity (Se) and
specificity (Sp) ) of
clinical variables  
for the diagnosis of
influenza.
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Figure 1 
ROC curve, model
with the two vari-
ables: time-period of
consultation (weeks
49–51, 52–1 and >1)
and duration of
symptoms before
first medical atten-
dance (<24 h, 24–48h,
>48h).
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Figure 2 
ROC curve, model with the four variables: time-period of
consultation (weeks 49–50, 51–5), duration of symptoms
before first medical attendance (<48h, >48h), continuous
temperature and cough.
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Figure 3
ROC curve, model with the four variables: time-period of
consultation (weeks 49–50, 51–5), duration of symptoms
before first medical attendance (<48h, >48h), temperature 
>37.8 °C and cough.
The present study shows that the best model
for the prediction of influenza in clinical practice
is the association of a duration between symptom
onset and first medical consultation of <48 hours,
medical attendance at the beginning of the epi-
demic, a temperature >37.8 °C, and cough. The
model was even better when we used temperature
as a continuous measurement, meaning that the
higher the temperature peaked, the better the pre-
diction. However in practice it is much easier to
use a fixed threshold (>37.8 °C).
Temperature >37.8 °C and cough were good
clinical predictors of influenza, which  is in line
with the results described in previous studies con-
ducted in selected populations aimed at assessing
the safety and efficacy of antiviral drugs [4–11, 13].
This means that primary care physicians can also
safely use these predictors to guide their practice.
Discussion
S W I S S  M E D  W K LY 2 0 0 5 ; 1 3 5 : 6 1 4 – 6 1 7  ·  w w w. s m w. c h 617
1 Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety
of the oral neuraminidase inhibitor oseltamivir in treating acute
influenza: a randomized, controlled trial. JAMA 2000;283:
1016–24.
2 Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy 
and safety of oseltamivir in treatment of acute influenza: a ran-
domized controlled trial. Lancet 2000;355:1845–50.
3 Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the
treatment of influenza A and B in high-risk patients. Arch In-
tern Med 2001;161:212–7.
4 Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J.
Clinical signs and symptoms predicting influenza infection.
Arch Intern Med 2000;160:3243–7.
5 Monmany J, Rabella N, Margall N, Domingo P, Gich I,
Vázquez G. Unmasking influenza virus infection in patients 
attended to in the Emergency Department. Infection 2004;32:
89–97.
6 Carrat F, Tachet A, Rouzioux C, Housset B, Valleron AJ. Eval-
uation of Clinical Case Definitions of Influenza: Detailed 
Investigation of Patients During the 1995–1996 Epidemic in
France. Clin Infect Dis 1999;28:283–90.
7 Zambon M, Hays J, Webster A, Newman R, Keene O. Diagno-
sis of influenza in the community: relationship of clinical diag-
nosis to confirmed virological, serological, or molecular detec-
tion of influenza. Arch Intern Med 2001;161:2116–22.
8 Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza
during epidemics with use of a clinical case definition. Clin 
Infect Dis 2000;31:1166–9.
9 van Elden LJR, van Essen GA, Boucher CAB, et al. Clinical
diagnosis of influenza virus infection: evaluation of diagnosis
tools in general practice Br J Gen Pract 2001;51:630–4.
10 Hulson TD, Mold JW, Scheid D, et al. Diagnosing influenza:
the value of clinical clues and laboratory tests. J Fam Pract
2001;50:1051–6.
11 Call SA, Vollenweider MA, Hornung CA, Simel DL, McKin-
ney WP. Does this patient have influenza? JAMA 2005;293:
987–97.
12 Swiss Sentinel Surveillance Network, Swiss Federal Office of
Public Health, CH-3003 Bern.
13 Friedman MJ, Attia MW. Clinical Predictors of influenza in
children. Arch Pediatr Adolesc Med 2004;158:391–4.
14 Ruest A, Michaud S, Deslandes S, Frost HF. Comparison of the
Directigen flu A+B test, the QuickVue influenza test, and clin-
ical case definition to viral culture and reverse transcription-
PCR for rapid diagnosis of influenza virus infection. J Clin 
Microbiol 2003;41:3487–93.
15 Rodriguez WJ, Schwartz RH, Thorne M. Evaluation of diag-
nostic tests for influenza in a pediatric practice. Pediatr Infect
Dis J 2002;21:193–6.
16 Boivin G, Hardy I, Kress A. Evaluation of a rapid optical im-
munoassay for influenza viruses (FLU OIA test) in comparison
with cell culture and reverse transcription-PCR. J clin Micro-
biol 2001;39:730–2.
References
According to our results, the timing of the
consultation must also be considered in the pres-
ence of clinical signs and symptoms suggesting
influenza. Indeed, duration of symptoms less than
48 hours, and first medical attendance at the be-
ginning of the epidemic were also good predictors
for the positive diagnosis of influenza in the pres-
ence of fever and cough. The primary care physi-
cian should therefore consider the  duration of
symptoms and the point of time during the epi-
demic when assessing the probability that his/her
patient has a diagnosis of influenza in the presence
of a known clinical predictor. 
In summary, the probability of having in-
fluenza is highest when the patient attends rapid-
ly after symptom onset, at the beginning of the
epidemic and in the presence of a temperature
>37.8 °C and cough. At the peak of the epidemic,
almost all patients have influenza, irrespective of
their symptoms and signs. The clinical predictors,
as well as the rapid diagnostic tests (due to the
important variability of specificity of these assays
[14–16]) thus lose their usefulness at that time. The
fact that the point of time of the consultation dur-
ing the epidemic influences the prediction of in-
fluenza, highlights the necessity for the clinician to
consider the epidemiological context at the time of
consultation, when estimating the probability of
his/her patient having influenza.  
The identification of clinical predictors of in-
fluenza, as well as a fair estimation of their variabil-
ity in time, should help to establish clinical scores
that could be used by the general practitioner to
optimise the care of patients in terms of rapid di-
agnostic tests use and antiviral therapy initiation.
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